secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEOGENOMICS INC (NEO)
CIK:        0001077183
Form:       8-K
Filed at:   2025-02-18T23:59:59+00:00
Accession:  0001077183-25-000024
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeoGenomics Q4 revenue +11% to $172M; FY24 $661M; guides FY25 rev $735-745M
---------------------------------------------------------------------------

- Q4 consolidated revenue $172M (up 11% YoY); net loss $15M vs $14M in Q4 2023.
- FY24 consolidated revenue $661M (+12% YoY); net loss $79M (improved from $88M).
- Adjusted EBITDA FY24 positive $40M vs $3M in 2023, a 1,036% increase.
- FY2025 guidance: revenue $735-745M (11-13% growth); adjusted EBITDA $55-58M.
- Ninth consecutive quarter of double-digit revenue growth; NGS grew 34% in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1077183/000107718325000024/0001077183-25-000024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1077183/000107718325000024/neo-20250218.htm
  HTML page:      https://secwatch.observer/filing/0001077183-25-000024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer